Logo image of SANA

SANA BIOTECHNOLOGY INC (SANA) Stock Fundamental Analysis

USA - NASDAQ:SANA - US7995661045 - Common Stock

3.99 USD
+0.33 (+9.02%)
Last: 11/14/2025, 8:25:05 PM
4.12 USD
+0.13 (+3.26%)
Pre-Market: 11/17/2025, 4:07:28 AM
Fundamental Rating

2

SANA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. The financial health of SANA is average, but there are quite some concerns on its profitability. SANA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SANA had negative earnings in the past year.
SANA had a negative operating cash flow in the past year.
In the past 5 years SANA always reported negative net income.
In the past 5 years SANA always reported negative operating cash flow.
SANA Yearly Net Income VS EBIT VS OCF VS FCFSANA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -69.73%, SANA is not doing good in the industry: 61.16% of the companies in the same industry are doing better.
With a Return On Equity value of -205.77%, SANA is not doing good in the industry: 68.29% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -69.73%
ROE -205.77%
ROIC N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
SANA Yearly ROA, ROE, ROICSANA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SANA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SANA Yearly Profit, Operating, Gross MarginsSANA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

SANA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SANA has more shares outstanding
SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SANA Yearly Shares OutstandingSANA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SANA Yearly Total Debt VS Total AssetsSANA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

SANA has an Altman-Z score of -6.08. This is a bad value and indicates that SANA is not financially healthy and even has some risk of bankruptcy.
SANA's Altman-Z score of -6.08 is on the low side compared to the rest of the industry. SANA is outperformed by 64.73% of its industry peers.
SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.08
ROIC/WACCN/A
WACCN/A
SANA Yearly LT Debt VS Equity VS FCFSANA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.47 indicates that SANA has no problem at all paying its short term obligations.
SANA has a worse Current ratio (2.47) than 69.04% of its industry peers.
SANA has a Quick Ratio of 2.47. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.
SANA has a Quick ratio of 2.47. This is in the lower half of the industry: SANA underperforms 66.98% of its industry peers.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 2.47
SANA Yearly Current Assets VS Current LiabilitesSANA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.91% over the past year.
EPS 1Y (TTM)41.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.24% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.98%
EPS Next 2Y19.39%
EPS Next 3Y11.37%
EPS Next 5Y8.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SANA Yearly Revenue VS EstimatesSANA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2032 50M 100M
SANA Yearly EPS VS EstimatesSANA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SANA. In the last year negative earnings were reported.
Also next year SANA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SANA Price Earnings VS Forward Price EarningsSANA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SANA Per share dataSANA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.39%
EPS Next 3Y11.37%

More info and screens

0

5. Dividend

5.1 Amount

SANA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (11/14/2025, 8:25:05 PM)

Premarket: 4.12 +0.13 (+3.26%)

3.99

+0.33 (+9.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners77.9%
Inst Owner Change11.22%
Ins Owners7.53%
Ins Owner Change0.07%
Market Cap982.98M
Revenue(TTM)N/A
Net Income(TTM)-252.18M
Analysts85.33
Price Target8.31 (108.27%)
Short Float %13.43%
Short Ratio6.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.4%
Min EPS beat(2)0.47%
Max EPS beat(2)10.32%
EPS beat(4)4
Avg EPS beat(4)5.41%
Min EPS beat(4)0.47%
Max EPS beat(4)10.32%
EPS beat(8)6
Avg EPS beat(8)12.12%
EPS beat(12)9
Avg EPS beat(12)9.29%
EPS beat(16)12
Avg EPS beat(16)8.83%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.07%
EPS NY rev (1m)-1.73%
EPS NY rev (3m)-14.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.02
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.5
TBVpS-0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.73%
ROE -205.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.01%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 2.47
Altman-Z -6.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)135.8%
Cap/Depr(5y)216.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y22.98%
EPS Next 2Y19.39%
EPS Next 3Y11.37%
EPS Next 5Y8.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.53%
EBIT Next 3Y6.09%
EBIT Next 5YN/A
FCF growth 1Y36.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.2%
OCF growth 3YN/A
OCF growth 5YN/A

SANA BIOTECHNOLOGY INC / SANA FAQ

Can you provide the ChartMill fundamental rating for SANA BIOTECHNOLOGY INC?

ChartMill assigns a fundamental rating of 2 / 10 to SANA.


What is the valuation status of SANA BIOTECHNOLOGY INC (SANA) stock?

ChartMill assigns a valuation rating of 0 / 10 to SANA BIOTECHNOLOGY INC (SANA). This can be considered as Overvalued.


Can you provide the profitability details for SANA BIOTECHNOLOGY INC?

SANA BIOTECHNOLOGY INC (SANA) has a profitability rating of 0 / 10.


How financially healthy is SANA BIOTECHNOLOGY INC?

The financial health rating of SANA BIOTECHNOLOGY INC (SANA) is 5 / 10.